Throne Biotechnologies is 2022’s Most Promising Leaders in Biotechnology – USA. The company is advanced – unlike anything else that is currently out there – and it is utilising its research to create permanent solutions for lifechanging illnesses, such as Type 1 Diabetes.

Throne Biotechnologies, also known simply as Throne, is a clinical-stage therapeutic company that boasts disruptive stem cell technology that has been proven to reverse Type 1 Diabetes (T1D), Alopecia Areata (AA), and other autoimmune diseases through immune education of Stem Cell Educator Therapy (Educator Therapy.) With three FDA-approved phase 2 INDs by using Educator Therapy to treat T1D, AA, and severe COVID-19 patients under its belt, it is abundantly clear that Throne is an international leader within the field.

‘Our 20 years of autoimmune disease research has revealed that many patients experience illness from damage to their spirit (trauma), lifestyle (bad habits), mind (stress), or relationship (abuse),’ explains Dr. Yong Zhao. ‘Stem Cell Educator® Therapy is more than an immune system reset for the body – it also provides a mental, spiritual, and lifestyle restoration.  Educator Therapy® is an integrated system of treating the whole person to fundamentally eradicate the root cause of the disease and restore immune balance, leading the improvement of patients’ quality of life.’ 

Throne Biotechnologies is the creation of Dr. Yong Zhao, for which he acts as the CEO and President. A pioneer, Dr. Yong Zhao was the first scientist to discover CB-SC stem cells from human cord blood and is the inventor of Stem Cell Educator Therapy to treat Type 1 Diabetes and other autoimmune diseases.

Over the years, he has held several esteemed positions, including scientist and professorship roles at Hackensack Meridian Health and the University of Illinois at Chicago. In addition, he holds nine patents and has been featured in 60 publications, CNN, USA Today, CBS, and additional major international news networks. His prior career as a physician informed his decision to delve into this area of research, through which he endeavours to create non-invasive cures for a plethora of diseases.

His contributions to the industry can be seen throughout Throne’s work. Indeed, his research began in 2005 with the discovery of cord blood-derived stem cells (CB-SC) from human cord blood, and by 2009 this had progressed to preclinical studies in diabetic mice. By 2010, clinical trials in Type 1 Diabetic patients took place, and were swiftly followed by international multi-centre clinical trials in the United States, China, and Spain. The FDA-approved second phase of clinical trials took place in 2019.

Moreover, in 2019, Throne provided the FDA with an application for Regenerative Medicine Advanced Therapy (RMAT) application, and it was accepted on the first two of the three criteria. The FDA reviewers requested additional clinical data from the second phase of its US trials, which is expected to strongly support its regenerative medicine advanced therapy (RMAT) requests for T1D and AA.

‘Educator therapy has the potential to revolutionise the treatment of T1D and eliminate the need for lifelong insulin therapy, without the safety and ethical concerns associated with conventional immune and/or stem cell-based approaches,’ he adds.

Whilst this journey has been incredibly successful, Throne has faced its fair share of challenges and setbacks. From acquiring funding to the Covid-19 pandemic, Throne and its team has had to overcome a multitude of hurdles in order to get to the position that it is currently in. Its persistence and determination have placed Throne as the developer of one of the few conventional immune therapies that have made it to phase 2 of FDA-approval – this is, quite rightly, something that it takes pride in.

The spectacular nature of Throne’s work has led it to be recognised by a number of prestigious organisations. For example, Throne’s patented Stem Cell Educator technology has been named by the Juvenile Diabetes Cure Alliance (JDCA) as the leading ‘Practical Cure Project’ for Type 1 Diabetes out of 590 global projects. Additionally, Throne was listed as of the ‘5 Best BioTech Companies to Watch’ in 2022 by The Silicon Review. From CNN to USA Today, Throne has been championed as a leader – an innovator – and its successes have been showcased on many internationally renowned media platforms.

Throne’s past has been filled with abundance, but what does its future look like? Dr. Yong Zhao notes, ‘Unlike the traditional model for drug marketing where a product is distributed through established channels, delivery of Educator Therapy will require the establishment of multiple treatment centres around the world through the Throne Business Model that combines an apheresis/infusion facility with a GMP production/treatment facility.’

Consequently, Throne’s GMP facility, which is located in Paramus, NJ, is currently applying for Foundation for the Accreditation of Cellular Therapy (FACT) accreditation, which establishes standards that Throne can use to implement a high quality medical and laboratory practice in cellular therapies. The Throne GMP facility will blossom from its current home in the New York metropolitan area and will delve into expanding throughout the United States and major global territories.

For business enquiries, contact Yong Zhao from Throne Biotechnologies on their website – ThroneBio.com